Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion-Positive Breast Cancer

JCO Precis Oncol. 2021 Jan 11:5:PO.20.00282. doi: 10.1200/PO.20.00282. eCollection 2021.

Authors

Satomi Watanabe^{1

1}, Masayuki Takeda^{1

1}, Tomoyuki Otani^{2

2}, Takeshi Yoshida^{1

1}, Kazuko Sakai^{3

3}, Elizabeth Olek^{4

4}, S Michael Rothenberg^{4

4}, Jennifer Kherani^{4

4}, Pearl P French^{5

5}, Kazuto Nishio^{3

3}, Akihiko Ito^{2

2}, Kazuhiko Nakagawa^{1

1}

Affiliations

¹ Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.
² Department of Pathology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.
³ Department of Genome Biology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.
⁴ Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company, Stamford, CT.
⁵ Eli Lilly and Company, Indianapolis, IN.

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Breast Neoplasms / chemistry
Breast Neoplasms / drug therapy*
Female
Humans
Middle Aged
Proto-Oncogene Proteins c-ret / analysis
Proto-Oncogene Proteins c-ret / antagonists & inhibitors*
Pyrazoles / therapeutic use*
Pyridines / therapeutic use*
Treatment Outcome

Substances

Pyrazoles
Pyridines
selpercatinib
Proto-Oncogene Proteins c-ret
RET protein, human